Overview

This advanced course is designed for healthcare professionals seeking to deepen their understanding of cutting-edge treatments for immune-mediated inflammatory diseases. Participants will critically appraise and integrate clinical data on the efficacy and toxicity of CAR T-cell therapies, cellular therapies, and other advanced treatments, aiming to identify strategies that could achieve long-term remission or cure.

Participants will also investigate and differentiate between infectious complications from biologic therapies and immune-related adverse events associated with checkpoint inhibitor therapies, formulating effective prevention and management strategies. The course will provide an in-depth examination of the mechanism of action of Janus kinase (JAK) inhibitors, their potential toxicities and adverse effects, particularly infection risks, to ensure optimal administration.

Additionally, participants will evaluate the efficacy and safety of IL-17 inhibitors (e.g., secukinumab, ixekizumab) and IL-23 inhibitors (e.g., ustekinumab, guselkumab) in treating immune-mediated inflammatory diseases, assessing the risks, including susceptibility to infections and long-term use implications. The latest advances in IL-23 inhibitors for immune-mediated inflammatory diseases will be explored, with a focus on emerging research and future clinical applications.

Finally, the course will critically evaluate emerging therapeutic strategies for difficult-to-treat conditions such as psoriatic arthritis (PsA), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and inflammatory myopathies, proposing innovative approaches to optimize patient outcomes based on current advancements.

Learning Objectives

• Critically appraise and integrate clinical data on the efficacy and toxicity of CAR T-cell therapies, cellular therapies, and other advanced treatments, with the objective of identifying and proposing strategies that could lead to long-term remission or cure of immune-mediated inflammatory diseases.
• Investigate and differentiate between infectious complications from biologic therapies and immune-related adverse events associated with checkpoint inhibitor therapies, while formulating effective prevention and management strategies.
• Examine the mechanism of action of Janus kinase (JAK) inhibitors in modulating immune responses, and identify the potential toxicities and adverse effects, particularly infection risks, to ensure the optimal administration of JAK inhibitors in patients.
• Evaluate the efficacy and safety of IL-17 inhibitors (e.g., secukinumab, ixekizumab) and IL-23 inhibitors (e.g., ustekinumab, guselkumab) in treating immune mediated inflammatory diseases, and assess the risks, including susceptibility to infections and the implications of long-term use.
• Explore and interpret the latest advances in IL-23 inhibitors for immune mediated inflammatory diseases, and assess their potential for treating other inflammatory conditions by examining emerging research and future clinical applications.
• Critically evaluate emerging therapeutic strategies for difficult-to-treat psoriatic arthritis (PsA), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and inflammatory myopathies, and propose innovative approaches to optimize patient outcomes based on current advancements.

Target Audience

The Summit is directed towards rheumatologists, allergists/immunologists, dermatologists, internal medicine physicians, nurse practitioners, nurses, and physician assistants interested in or using biologic therapeutics for autoimmune and autoinflammatory disorders.

Accreditation

Cleveland Clinic Center for Continuing Education designates this live activity for a maximum of 10.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For more information please visit the official event page.